TFE3 and renal cell carcinoma: Hit compounds were identified that demonstrated an effect in all 3 cell lines and pathway analysis of these hit compounds highlighted enrichment for five classes of agents with potential pharmacological efficacy against the TFE3-fusion RCC cell lines, including inhibitors of the phosphoinositide-3-kinase (PI3K) / mechanistic target of rapamycin (mTOR) pathway, histone deacetylases (HDAC), tubulin, proteasome, and Src/Abl kinases (Fig. 2A,B).